Up next
Author
Share article
The post has been shared by 0 people.
Facebook 0
X (Twitter) 0
Pinterest 0
Mail 0

What if scientists could switch genes on or off without permanently altering DNA? That’s exactly what a new wave of CRISPR technology is making possible. It’s called epigenetic editing, and it’s changing how researchers think about treating disease.

Traditional CRISPR-Cas9 works like molecular scissors. It cuts DNA at specific spots using a guide RNA. Scientists Jennifer Doudna and Emmanuelle Charpentier adapted this natural bacterial defense system in 2012 for use in humans. It made DNA editing faster, cheaper, and easier than ever before.

Now researchers have taken it further. They’ve modified Cas9 so it doesn’t cut DNA at all. This version, called dead Cas9 or dCas9, latches onto chemical markers on DNA instead. It can add or remove these markers to turn genes on or off. The DNA sequence itself stays untouched.

Dead Cas9 doesn’t cut — it controls. Same DNA, new behavior, infinite possibility.

One key method removes methyl groups from silenced genes to wake them back up. Another deposits repressive marks like H3K9me3 to shut genes down. These chemical tags are part of what scientists call the epigenome. It’s a layer of controls sitting on top of the DNA code.

The results have been striking. A tool called CRISPRoff 7 silenced genes in human T cells at 85-99% efficiency with no toxicity. That silencing lasted 28 days through 30-80 cell divisions.

Scientists also successfully silenced three to five genes at once, with efficiency rates between 65.8% and 93.5%.

These advances have real medical potential. Researchers have reactivated fetal hemoglobin to treat sickle cell disease. They’ve also used epigenetic editing to improve CAR-T cell therapy for cancer patients. Gene activation has ranged from 3-fold to an impressive 6,500-fold increase in targeted genes.

Teams at UNSW and St. Jude Children’s Research Hospital are testing these methods in animal models. Mouse studies have shown liver-specific gene control using both repressors and activators. Enhancers, which fine-tune gene transcription levels, can be activated using dCas9-p300 fusion, directly influencing how target genes are expressed across tissues.

Scientists say this technology could address conditions caused by improper gene regulation, not just DNA mutations. Researchers are also advancing new editing tools like base editing and prime editing, with AI integration accelerating discovery in the field. It’s the start of a new era in precision medicine, and it’s moving fast.

References